Mekinist (trametinib) 2 mg, 30 tablets, generic, Bangladesh Order Mekinist (trametinib) 2 mg, 30 tablets, generic, Bangladesh. Medicine delivery from Europe within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.
- Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment. - Pickup from Odesafree
- Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.
Delivery time
- Originator medicines: 5-7 days
- Generic medicines: 3-4 days
- Bank transfer to the settlement account after receiving the order
- Payment upon pickup in Odesa
Indications
Trametinib is indicated as monotherapy for the treatment of patients with inoperable or metastatic melanoma with braf V600e or V600k mutations not previously treated with braf inhibitors.6,8
It is used in combination with dabrafenib for:
treatment of unresectable or metastatic melanoma with BRAF V600E or mutations V600K.7
adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and lymph node involvement after complete resection.7,8
treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF mutation V600E.7 In Europe, it is indicated for the treatment of adult patients with advanced non-small cell lung cancer with the BRAF V600.8 mutation
treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ARTC) with the BRAF V600E mutation and lack of satisfactory locoregional treatment options.7
Treatment of adults and children six years of age and older with unresectable or metastatic solid tumors with the BRAF V600E mutation who have had disease progression after prior treatment and have no satisfactory alternative treatment options. In the United States, this indication received accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on confirmation and description of clinical benefit in confirmatory study(s).7
Treatment of children one year of age and older with low-grade glioma (LGG) with the BRAF V600E mutation who require systemic therapy.7
